We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Opdivo

News List

NICE recommends against Opdivo for classical Hodgkin lymphoma pharmafile
March 16, 2017
The National Institute of Health and Care Excellence (NICE) has released draft guidance provisionally turning down Bristol-Myers Squibb’s Opdivo (nivolumab)...
NICE asks for more data on Opdivo pharmatimes
March 16, 2017
The National Institute for Health and Care Excellence has published draft guidelines recommending that Bristol ...
Bristol-Myers Squibb won't seek accelerated US approval of Opdivo, Yervoy combination in first-line firstwordpharma
January 22, 2017
Bristol-Myers Squibb announced that it will not pursue an accelerated regulatory pathway for the combination of Opdivo (nivolumab) plus Yervoy (ipilimumab) in first-line lung cancer in the US based on a review of current data.
Opdivo demonstrated efficacy and improved survival in patients with previously treated advanced gast cphi-online
January 20, 2017
Opdivo demonstrated a 37% reduction in the risk of death compared to placebo.
BMS and Janssen to collaborate to evaluate Opdivo in combination with Darzalex cphi-online
January 09, 2017
Phase Ib/II studies to explore a novel immuno-oncology combination in hematological and solid tumours with high unmet medical need.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page